28209454|t|Treatment of Carcinoma In Situ of the Glans Penis With Topical Imiquimod Followed by Carbon Dioxide Laser Excision
28209454|a|Different approaches have been described in published studies for carcinoma in situ (CIS) of the glans penis (erythroplasia of Queyrat), including topical chemotherapy or immunotherapy and laser or surgical excision. We evaluated the efficacy of topical imiquimod (IQ) followed by carbon dioxide laser ablation of the lesion. From 2010 to 2015, 10 patients affected by CIS of the glans were treated by IQ, followed by carbon dioxide laser ablation. For every patient, we performed histologic examination before and after IQ. Local toxicity and adverse effects were recorded. After treatment, histologic examination showed no residual tumor in 6 patients (complete response [CR]), stable disease in 2 patients, and progressive disease in 2 patients. Those with a CR had human papillomavirus - related lesions, and they had no experienced relapses after a mean follow-up of 26 months. The 2 patients with progressive disease underwent total penectomy. All patients were alive at the last follow-up examination. All patients experienced a mild local toxicity (burning erythema) but no major adverse effects. Local treatment with IQ for glans CIS is effective mainly for human papillomavirus - related lesions. The present study is the first to record the histologic examination findings before and after IQ treatment. The small number of patients, owing to the rarity of this disease, was the main limitation of the present study. IQ must be used carefully, and a close follow-up protocol is mandatory because of the lack of long-term efficacy data.
28209454	0	9	Treatment	T169	C0039798
28209454	13	49	Carcinoma In Situ of the Glans Penis	T191	C0686217
28209454	55	72	Topical Imiquimod	T200	C3215046
28209454	85	105	Carbon Dioxide Laser	T074	C0392251
28209454	106	114	Excision	T061	C0728940
28209454	115	124	Different	T080	C1705242
28209454	125	135	approaches	T169	C1292724
28209454	146	155	described	T078	C1552738
28209454	181	223	carcinoma in situ (CIS) of the glans penis	T191	C0686217
28209454	225	249	erythroplasia of Queyrat	T191	C0154089
28209454	252	261	including	T169	C0332257
28209454	262	282	topical chemotherapy	T061	C1519552
28209454	286	299	immunotherapy	T061	C0021083
28209454	304	309	laser	UnknownType	C0441543
28209454	313	330	surgical excision	T061	C0728940
28209454	335	344	evaluated	T061	C0728940
28209454	349	357	efficacy	T080	C1280519
28209454	361	378	topical imiquimod	T200	C3215046
28209454	380	382	IQ	T200	C3215046
28209454	396	416	carbon dioxide laser	T074	C0392251
28209454	417	425	ablation	T061	C0348007
28209454	433	439	lesion	T033	C0221198
28209454	463	480	patients affected	T080	C0522476
28209454	484	487	CIS	T191	C0686217
28209454	495	500	glans	T023	C1550261
28209454	506	513	treated	T061	C0332293
28209454	517	519	IQ	T200	C3215046
28209454	533	553	carbon dioxide laser	T074	C0392251
28209454	554	562	ablation	T061	C0348007
28209454	574	581	patient	T101	C0030705
28209454	586	595	performed	T169	C0884358
28209454	596	618	histologic examination	T059	C0019637
28209454	619	625	before	T079	C0332152
28209454	630	635	after	T079	C0687676
28209454	636	638	IQ	T200	C3215046
28209454	646	654	toxicity	T037	C0013221
28209454	659	674	adverse effects	T046	C0879626
28209454	690	705	After treatment	T079	C2709088
28209454	707	729	histologic examination	T059	C0019637
28209454	737	754	no residual tumor	T034	C0332652
28209454	760	768	patients	T101	C0030705
28209454	770	787	complete response	T033	C4050307
28209454	789	791	CR	T033	C4050307
28209454	795	809	stable disease	T033	C0677946
28209454	815	823	patients	T101	C0030705
28209454	829	848	progressive disease	T047	C1335499
28209454	854	862	patients	T101	C0030705
28209454	877	879	CR	T033	C4050307
28209454	884	904	human papillomavirus	T005	C0021344
28209454	907	914	related	T080	C0439849
28209454	915	922	lesions	T033	C0221198
28209454	937	939	no	T033	C1513916
28209454	952	960	relapses	T067	C0035020
28209454	961	966	after	T079	C0687676
28209454	974	983	follow-up	T058	C1522577
28209454	990	996	months	T079	C0439231
28209454	1004	1012	patients	T101	C0030705
28209454	1018	1037	progressive disease	T047	C1335499
28209454	1054	1063	penectomy	T061	C0194708
28209454	1069	1077	patients	T101	C0030705
28209454	1083	1088	alive	T033	C2584946
28209454	1101	1122	follow-up examination	T033	C0260832
28209454	1128	1136	patients	T101	C0030705
28209454	1151	1155	mild	T080	C2945599
28209454	1162	1170	toxicity	T037	C0013221
28209454	1172	1188	burning erythema	T184	C0085624
28209454	1194	1196	no	T033	C1513916
28209454	1197	1202	major	T080	C0205164
28209454	1203	1218	adverse effects	T046	C0879626
28209454	1226	1235	treatment	T169	C0039798
28209454	1241	1243	IQ	T200	C3215046
28209454	1248	1253	glans	T023	C1550261
28209454	1254	1257	CIS	T191	C0686217
28209454	1261	1270	effective	T080	C1704419
28209454	1282	1302	human papillomavirus	T005	C0021344
28209454	1305	1312	related	T080	C0439849
28209454	1313	1320	lesions	T033	C0221198
28209454	1367	1389	histologic examination	T059	C0019637
28209454	1399	1405	before	T079	C0332152
28209454	1410	1415	after	T079	C0687676
28209454	1416	1418	IQ	T200	C3215046
28209454	1419	1428	treatment	T169	C0039798
28209454	1450	1458	patients	T101	C0030705
28209454	1473	1479	rarity	T080	C0522498
28209454	1488	1495	disease	T047	C0012634
28209454	1510	1520	limitation	T169	C0449295
28209454	1543	1545	IQ	T200	C3215046
28209454	1582	1591	follow-up	T058	C1522577
28209454	1592	1600	protocol	T170	C0442711
28209454	1604	1613	mandatory	T061	C0683517
28209454	1629	1633	lack	T080	C0332268
28209454	1637	1646	long-term	T079	C0443252
28209454	1647	1655	efficacy	T080	C1280519